| abstract |
The invention provides compounds of formula (I), wherein R?1 and R2¿ independently represent H or C¿1-6? alkyl; R?3¿ represents phenyl substituted by at least one group selected form halo, CF¿3?, OCF3, CN, OH, C1-6 alkyl and C1-6 alkoxy; and R?4, R5 and R11¿ independently represent H or -(CH¿2?)n-A, wherein n represents 0, 1 or 2, provided that at least one of R?4, R5 and R11¿ is other than H; A represents CONR6R7 or SO¿2NR?6R7, wherein R?6 and R7¿ independently represent H, C¿3-6? cycloalkyl or C1-6 alkyl, the C?1-6¿ alkyl group being optionally substituted, in addition, R?6 and R7¿ may, together with the N atom to which they are attached, represent a ring which is optionally substituted; CO¿2R?8, wherein R8 represents H or C¿1-6? alkyl; NR?9R10¿, wherein R?9 and R10¿ independently represent H, C¿1-6? alkyl (optionally substituted), (C1-6 alkyl)SO2-, (C1-6 alkyl)CO-, H2NSO2- or H2NCO-; a 5- or 6-membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, S and O, which is optionally substituted; S(O)x(C1-6 alkyl), wherein x represents 0, 1 or 2; OH; CN, NO2; or C1-6 alkoxy which is optionally substituted; provided that when NR?1R2¿ represents N(H) methyl, R4 represents H and R3 represents 4- chlorophenyl, then R5 does not represent methoxy; and pharmaceutically acceptable salts thereof. The compounds of the invention are useful in the treatment or prevention of a variety of disorders, including those in which the regulation of monoamine transporter function is implicated. |